Poslední aktualizace :
06/05/2024
Antiemetikum   Granisetron hydrochloride  
Injekce
Perorální roztok
Stabilita roztoků Stabilita směsí Faktory ovlivňující stabilitu Kompatibilita Způsoby aplikace Odkazy Pdf
   Chemický vzorec  

Obchodní název   Obchodní název     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Axigran NÏmecko, Saúdská Arábie
Cadigran Indie
Cetrexon Kolumbie
Em Ex Egypt
Emegran Indie
Emetril Turecko
Grandem Indie
Granic Írán
Granicip Indie
Graniset Indie
Granisetrom Portugalsko
Granisetron äpanÏlsko, Belgie, Chile, Egypt, Ekvádor, Kanada, Mexiko, Peru, Rumunsko, Saúdská Arábie, Švédsko, USA, Velká Británie
Granitero Portugalsko
Granitron Rakousko
Granon Indie
Granytril Indie
Gratil Írán
Gratryl Turecko
Helminar Peru
Kevatril NÏmecko
Kytril äpanÏlsko, Austrálie, Belgie, BrazÌlie, Chile, Dánsko, Egypt, Ekvádor, Finsko, Írán, Irsko, Itálie, Japonsko, Kolumbie, Lucembursko, Malajsie, MaÔarsko, Maroko, Mexiko, NÏmecko, Nizozemsko, Peru, Polsko, Portugalsko, Rakousko, Saúdská Arábie, Spojené arabské emiráty, Švédsko, Švýcarsko, Tunisko, Turecko, Velká Británie, Venezuela, ÿecko
Manotrox Mexiko
Neoset Turecko
Ribosetron NÏmecko
Rubrum Venezuela
Suliftop Peru
Synarex Turecko
Tentratec Mexiko
Tigron Turecko
Travigan Mexiko
Trilemes Mexiko
Vitasetron Turecko
Odkazy   Injekce   Odkazy : Granisetron hydrochloride  
Typ Uveřejnění
6 Noviny Trissel LA, Xu QA, Martinez JF, Fox JL.
Compatibility and stability of ondansetron hydrochloride with morphine sulfate and with hydromorphone hydrochloride in 0.9% sodium chloride injection at 4, 22 and 32°C.
Am J Hosp Pharm 1994 ; 51: 2138-2142.
27 Noviny Chin A, Moon YSK, Chung KC, Gill MA.
Stability of granisetron hydrochloride with dexamethasone sodium phosphate for 14 days.
Am J Health-Syst Pharm 1996 ; 53: 1174-1176.
29 Noviny Pinguet F, Rouanet P, Martel P, Fabbro M, Salabert D, Astre C.
Compatibility and stability of granisetron, dexamethasone, and methylprednisolone in injectable solutions.
J Pharm Sci 1995 ; 84: 267-268.
48 Noviny Quercia RA, Zhang J, Fau C, Chow MSS.
Stability of granisetron hydrochloride in polypropylene syringes.
Am J Health-Syst Pharm 1996 ; 53: 2744-2746.
49 Noviny Trissel LA, Martinez JF.
Compatibility of granisetron hydrochloride with selected alkaline drugs.
Am J Health-Syst Pharm 1995 ; 52: 208.
51 Noviny Chung KC, Chin A, Gill MA.
Stability of granisetron hydrochloride in a disposable elastomeric infusion device.
Am J Health-Syst Pharm 1995 ; 52: 1541-1543.
57 Noviny Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
182 Noviny Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
249 Noviny Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Noviny Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300 Noviny Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Noviny Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
921 Noviny Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1026 Noviny Mayron D, Gennaro AR.
Stability and compatibility of topotecan hydrochloride with selected drugs.
Am J Health-Syst Pharm 1999 ; 56: 875-881.
1410 Noviny Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Noviny Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Noviny Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1496 Noviny Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428.
1625 Noviny Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1633 Noviny Walker SE, Law S.
Stability and compatibility of granisetron alone and in combination with dexamethasone in 0.9% sodium chloride and 5% dextrose in water solutions.
Can J Hosp Pharm 2002 ; 55: 27-38.
1662 Noviny Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1676 Noviny Hourcade F, Sautou-Miranda V, Normand B, Laugier M, Picq F, Chopineau J.
Compatibility of granisetron towards glass and plastics and its stability under various storage conditions.
Int J Pharm 1997 ; 154: 95-102.
1712 Noviny Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1721 Noviny Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1754 Noviny Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1803 Noviny Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925 Noviny Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1953 Noviny Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
2262 Noviny Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269 Noviny Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2335 Noviny Canann D, Tyler L.S, Barker B, Condie C.
Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients
Am J Health-Syst Pharm 2009 ; 66, 8: 727-729
3249 Noviny Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3459 Noviny Sun S, Schaller J, Placek J, Duersch B.
Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids.
Cancer Chemother Pharmacol 2013 ; 72: 509-513.
3571 Noviny Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M.
Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration.
Hosp Pharm 2014 ; 49, 1: 42-47.
3805 Noviny Chen F.C, Xiong H, Liu H.M, Fang B.X, Li P.
Compatibility of butorphanol with granisetron in 0.9% sodium chloride injection packaged in glass bottles or polyolefin bags.
Am J Health-Syst Pharm 2015 ; 72:1374-1378.
3824 Noviny Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98
3964 Noviny Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
4061 Noviny Wu George, Powers Dan, Yeung S, Chen F, Neelon K.
Compatibility and stability of VARUBI (Rolapitant) injectable emulsion admixed with intravenous granisetron hydrochloride.
Int J Pharm Compound 2018 ; 22,1 :86-94
4116 Noviny Chen F, Zhu J, Li B, Yuan F, Wang K.
Stability of tramadol with three 5-HT3 receptor antagonists in polyolefin bags for patient-controlled delivery systems.
Drug Design Dev Ther 2016 ;10:1869-1875
4310 Noviny Mizuta N, Nakagawa T, Yamamoto K, Nishioka T, Kume M, Makimoto H, Yano I, Minami H, Hiral M.
Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs.
Kaohsiung J Med Sci 2017 ; 63, 1: E9-E16.
4319 Noviny Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4429 Noviny Fang B-X, Li P, Shi X-Y, Chen F.C, Wang L.H.
Incompatibilities of lornoxicam with 4 antiemetic medications in polyolefin bags during simulated intravenous administration.
Medicine 2016 ; 95:25(e3824)
4603 Noviny Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4742 Noviny Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.

  Mentions Légales